AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1996738 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (1 mg oral dose)
Number of subjects: 30
Study 1996738 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 30
Study 6340972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac 400 mg daily
Number of subjects: 40
Study 6340972 — intervention group
Group type: COMPARATOR
Intervention: Sulindac 200 mg daily
Number of subjects: 40
Study 6340972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac
Number of subjects: 40
Study 6340972 — intervention group
Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 40
Study 6340972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac (long-term tolerance study)
Number of subjects: 40
Study 29505867 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMBRE intervention (culturally adapted intervention providing individual choice of self‐directed online videos, coach‐facilitated in‐person groups, and coach‐facilitated online groups)
Number of subjects: 424
Study 29505867 — intervention group
Group type: COMPARATOR
Intervention: Minimal intensity intervention (uses online videos with a coach available, if solicited by the participant)
Number of subjects: 424
Study 29505867 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMBRE intervention
Number of subjects: 424
Study 26718792 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 80mg
Number of subjects: 318
Study 26718792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 25245218 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT with 20 mg/m2 cisplatin for 5 days
Number of subjects: 192
Study 25245218 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 192
Study 25245218 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT
Number of subjects: 192
Study 21848925 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based blood glucose monitoring system (submitted weekly for 6 months)
Number of subjects: 70
Study 21848925 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine follow-up, no submission of blood glucose levels)
Number of subjects: 70
Study 20348185 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 30
Study 20348185 — intervention group
Group type: COMPARATOR
Intervention: Education in Successful Aging (SA)
Number of subjects: 30
Study 17440420 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion threshold (10 g/dL hemoglobin)
Number of subjects: 1699
Study 17440420 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion threshold (7 g/dL hemoglobin)
Number of subjects: 1699
Study 17440420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (6 mL/kg)
Number of subjects: 1699
Study 17440420 — intervention group
Group type: COMPARATOR
Intervention: High tidal volume (12 mL/kg)
Number of subjects: 1699
Study 15629618 — intervention group
Group type: EXPERIMENTAL
Intervention: Head mask (HM)
Number of subjects: 260
Study 15629618 — intervention group
Group type: COMPARATOR
Intervention: Head-and-shoulder mask (HSM)
Number of subjects: 260
Study 12384647 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (L-A) infusion at a rate of 1.5 g/min for 20 min
Number of subjects: 15
Study 12384647 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 15
Study 9563145 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenyline 10 mg b.i.d. (n = 71)
Number of subjects: 190
Study 9563145 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg q.d. (n = 54)
Number of subjects: 190
Study 9563145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dibenyline and finasteride (n = 65)
Number of subjects: 190
Study 7826784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (up to 7%)
Number of subjects: 50
Study 7826784 — intervention group
Group type: COMPARATOR
Intervention: Halothane (up to 3.5%)
Number of subjects: 50
Study 7826784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 7826784 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 50
Study 7826784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Halothane
Number of subjects: 50
Study 3415462 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial reconstruction (group 1)
Number of subjects: 80
Study 3415462 — intervention group
Group type: COMPARATOR
Intervention: CA ligation or non‐operative management (group 2)
Number of subjects: 80
Study 3415462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonocclusive injuries managed nonoperatively (group 3)
Number of subjects: 80
Study 31684943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM) implementation with external expert support (5 days provided)
Number of subjects: 42
Study 31684943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM) implementation
Number of subjects: 42
Study 31684943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM) training
Number of subjects: 42
Study 29790479 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES; Ultimaster)
Number of subjects: 1101
Study 29790479 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer everolimus-eluting stent (PP-EES; XIENCE)
Number of subjects: 1101
Study 27630504 — intervention group
Group type: EXPERIMENTAL
Intervention: Perio Q(TM) gel + SRP
Number of subjects: 15
Study 27630504 — intervention group
Group type: EXPERIMENTAL
Intervention: tea tree oil gel + SRP
Number of subjects: 15
Study 27630504 — intervention group
Group type: COMPARATOR
Intervention: placebo gel + SRP
Number of subjects: 15
Study 24995473 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone impressions
Number of subjects: 85
Study 24995473 — intervention group
Group type: COMPARATOR
Intervention: Alginate impressions
Number of subjects: 85
Study 24995473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both impressions
Number of subjects: 85
Study 23249098 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for 32 weeks
Number of subjects: 2
Study 23249098 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for 20 weeks
Number of subjects: 2
Study 23249098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 21041813 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g/d oligofructose-enriched inulin in a calcium-fortified cereal
Number of subjects: 14
Study 21041813 — intervention group
Group type: COMPARATOR
Intervention: Control cereal with no inulin
Number of subjects: 14
Study 16616075 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit perceptual information on object colour during sentence comprehension
Number of subjects: 0
Study 16616075 — intervention group
Group type: COMPARATOR
Intervention: Matching colour condition
Number of subjects: 0
Study 15720735 — intervention group
Group type: EXPERIMENTAL
Intervention: FTIR‐ATR analysis of hair from breast cancer patients
Number of subjects: 32
Study 15720735 — intervention group
Group type: COMPARATOR
Intervention: FTIR‐ATR analysis of hair from healthy subjects
Number of subjects: 32
Study 15720735 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind study using FTIR‐ATR spectral differences as markers
Number of subjects: 32
Study 11914244 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain rate imaging (SRI) postablation
Number of subjects: 10
Study 11914244 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain rate imaging (SRI) comparing infarct and noninfarct areas
Number of subjects: 10
Study 11914244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging (TDI) pre- and postablation
Number of subjects: 10
Study 11914244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging (TDI) comparing infarct and noninfarct areas
Number of subjects: 10
Study 11914244 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI analysis
Number of subjects: 10
Study 9730069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mucosal adhesive film containing dibucaine (DC) at a dose of 0.113 mg/cm2
Number of subjects: 23
Study 9730069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mucosal adhesive film containing dibucaine (DC) at a dose of 0.225 mg/cm2
Number of subjects: 23
Study 8137516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg i.v.
Number of subjects: 8
Study 8137516 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-releasing hormone 1 microgram/kg body weight
Number of subjects: 8
Study 8137516 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-releasing hormone without dexamethasone pretreatment
Number of subjects: 8
Study 8137516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8137516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 8
Study 2605801 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of perindopril
Number of subjects: 0
Study 2605801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of perindopril
Number of subjects: 0
Study 2605801 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of perindopril
Number of subjects: 0
Study 1159330 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin sulfate (1.5 mg/kg) intravenous injection
Number of subjects: 6
Study 1159330 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin sulfate (1.5 mg/kg) intramuscular injection
Number of subjects: 6
Study 7362050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 54
Study 7362050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 54
Study 7362050 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine
Number of subjects: 54
Study 7362050 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 54
Study 31605587 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-Free General Anesthesia (OFA)
Number of subjects: 60
Study 31605587 — intervention group
Group type: COMPARATOR
Intervention: General balanced anesthesia with fentanyl (F group - FG)
Number of subjects: 60
Study 28678332 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength group (oral hypoglycemic medications, subcutaneous insulin infusion, or continuous infusion by micropump)
Number of subjects: 90
Study 28678332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitigation group (personalized treatment programs)
Number of subjects: 90
Study 28678332 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet and exercise)
Number of subjects: 90
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (specific intervention not detailed)
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Whites
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Blacks
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with hemoglobin A1c < 7.0%
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not maintain glycemic control at 6 months
Number of subjects: 679
Study 26047470 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS classifications
Number of subjects: 679
Study 23422399 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 55
Study 23422399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21551998 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated water intake
Number of subjects: 40
Study 21551998 — intervention group
Group type: COMPARATOR
Intervention: Tap water intake (Control)
Number of subjects: 40
Study 18390917 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill and cycling exercise (30‐90 min, three to five times per week) at a HR corresponding to 50% of peak oxygen uptake (VO2peak)
Number of subjects: 326
Study 17342002 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational and HF management program
Number of subjects: 40
Study 17342002 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 40
Study 15087793 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid arthrodesis
Number of subjects: 47
Study 15087793 — intervention group
Group type: COMPARATOR
Intervention: Pseudarthrosis
Number of subjects: 47
Study 11834234 — intervention group
Group type: EXPERIMENTAL
Intervention: Leios (0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel)
Number of subjects: 67
Study 11834234 — intervention group
Group type: EXPERIMENTAL
Intervention: Stediril 30 (0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel)
Number of subjects: 67
Study 11834234 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 67
Study 9609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 618
Study 9609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.8 mg
Number of subjects: 618
Study 9609624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 7825009 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect enzyme‐linked immunosorbent assay (ELISA) using 31.5 kDa antigen
Number of subjects: 0
Study 7825009 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot analysis using 31.5 kDa antigen
Number of subjects: 0
Study 3278498 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25‐50 mg bolus plus infusion, 5‐7.5 mg h‐1) in lactated Ringer solution
Number of subjects: 100
Study 3278498 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution
Number of subjects: 100
Study 30573769 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group format treatment (6 sessions, 2 hours each, one session per week)
Number of subjects: 81
Study 30573769 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group format treatment
Number of subjects: 81
Study 30573769 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 81
Study 28800067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountain hiking
Number of subjects: 42
Study 28800067 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor treadmill walking
Number of subjects: 42
Study 28800067 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 42
Study 26258447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 11
Study 26258447 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch
Number of subjects: 11
Study 26258447 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough touch
Number of subjects: 11
Study 26258447 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 11
Study 26258447 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement distance and peak velocity during forward-reaching task
Number of subjects: 11
Study 23243212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxentan
Number of subjects: 27
Study 23243212 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 27
Study 23243212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21778256 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-caloric exercise condition (longer-distance walking)
Number of subjects: 38
Study 21778256 — intervention group
Group type: COMPARATOR
Intervention: Lower-caloric-expenditure exercise group
Number of subjects: 38
Study 18712387 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal midshaft centralising device (PCD)
Number of subjects: 30
Study 18712387 — intervention group
Group type: COMPARATOR
Intervention: Distal centralising device (DCD)
Number of subjects: 30
Study 17147285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 0
Study 17147285 — intervention group
Group type: COMPARATOR
Intervention: Natural progression of the disease
Number of subjects: 0
Study 31347489 — intervention group
Group type: EXPERIMENTAL
Intervention: Test canagliflozin formulation (100 mg)
Number of subjects: 55
Study 31347489 — intervention group
Group type: COMPARATOR
Intervention: Reference canagliflozin formulation (100 mg)
Number of subjects: 55
Study 31347489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 55
Study 10599729 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group A, 4 IU/m2 x day
Number of subjects: 68
Study 10599729 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group B, first year 4 and thereafter 6 IU/m2 x day
Number of subjects: 68
Study 10599729 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group C, first year 4, second year 6, and thereafter 8 IU/m2 x day
Number of subjects: 68
Study 10599729 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment groups A, B, C
Number of subjects: 68
Study 10599729 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group A
Number of subjects: 68
Study 8738724 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha 2b interferon (3 MIU, subcutaneously, three times a week for 4 months)
Number of subjects: 41
Study 8738724 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control group)
Number of subjects: 41
Study 8738724 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha 2b interferon
Number of subjects: 41
Study 1932297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 90
Study 1932297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime with amikacin (1.5 g/day)
Number of subjects: 90
Study 6211997 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin infusion
Number of subjects: 22
Study 6211997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 22
Study 30996060 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 667
Study 30996060 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 667
Study 30996060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 29441949 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (first day)
Number of subjects: 42
Study 29441949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 42
Study 27480145 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil-radiotherapy
Number of subjects: 495
Study 27480145 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6-radiotherapy
Number of subjects: 495
Study 27480145 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Number of subjects: 495
Study 24622752 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control and physical activity intervention (15 visits from a dietitian over 3 years)
Number of subjects: 171
Study 24622752 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 visits over 3 years)
Number of subjects: 171
Study 24622752 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control and physical activity intervention
Number of subjects: 171
Study 22100576 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir-ritonavir
Number of subjects: 21
Study 22100576 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir-ritonavir
Number of subjects: 21
Study 22100576 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, non-opioid-dependent volunteers)
Number of subjects: 21
Study 20339034 — intervention group
Group type: COMPARATOR
Intervention: Segmental pulmonary vein isolation (PVI)
Number of subjects: 66
Study 20339034 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation plus left atrial linear ablation (CPVA+LALA)
Number of subjects: 66
Study 18358082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg
Number of subjects: 1011
Study 18358082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 1011
Study 18358082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 1011
Study 18358082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 400 mg
Number of subjects: 1011
Study 18358082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1011
Study 16463883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive cerebrovascular autoregulation (CA) monitoring using ultrasonic 'time-of-flight' monitor (Vittamed)
Number of subjects: 13
Study 16463883 — intervention group
Group type: COMPARATOR
Intervention: Invasive cerebrovascular autoregulation (CA) monitoring
Number of subjects: 13
Study 16463883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive cerebrovascular autoregulation (CA) monitoring
Number of subjects: 13
Study 16463883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive cerebrovascular autoregulation (CA) estimation
Number of subjects: 13
Study 12849808 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed hormone therapy (CEE)
Number of subjects: 108
Study 12849808 — intervention group
Group type: COMPARATOR
Intervention: Opposed hormone therapy (CEE and medroxyprogesterone acetate)
Number of subjects: 108
Study 12849808 — intervention group
Group type: COMPARATOR
Intervention: Tibolone
Number of subjects: 108
Study 12849808 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 108
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sun exposure due to residence or occupation
Number of subjects: 351
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the city but spending 50% of time in rural areas for holidays
Number of subjects: 351
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunbathing more than 30 times a year
Number of subjects: 351
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor leisure time with exposure greater than 60 units in the last 2 years
Number of subjects: 351
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Construction workers
Number of subjects: 351